Regulatory Intelligence Built for Life Sciences.

AcceleraQA is an AI-enabled regulatory intelligence platform and publishing company serving pharmaceutical, biotech, medical device, and CRO organizations. We help quality directors, compliance specialists, data managers, and regulatory affairs professionals stay current with evolving regulations, anticipate inspection focus areas, and build quality systems that regulators trust.

Regulatory intelligence means continuously monitoring what regulators are saying, doing, and finding — and translating that into actionable insight for your organization. AcceleraQA tracks guidance documents, enforcement actions, warning letters, inspection trends, and regulatory announcements from FDA, EMA, ICH, MHRA, and other bodies, then uses AI to surface what matters to your specific programs and quality systems.

Traditional regulatory information services deliver documents. AcceleraQA delivers interpretation. Our AI doesn't just index regulatory text — it analyzes the enforcement record, maps current inspection patterns, and connects guidance changes to operational implications for your quality system. We combine AI-powered monitoring with expert practitioner publishing to give you intelligence you can act on, not just read.

AcceleraQA publishes practitioner-level guidance for regulated industry professionals. Our debut title, Data Integrity By Design: Building Systems That Regulators Trust by Christopher L. Gent, draws on the FDA enforcement record and global regulatory frameworks to give quality teams a design-based approach to data integrity. Future publications will address inspection readiness, computer system validation, and emerging regulatory challenges.

AcceleraQA maps your quality system against current inspection patterns and enforcement trends using the same analytical methods FDA BIMO and EU GCP investigators apply. The platform identifies gaps between your documented systems and operational reality, scores readiness by compliance area, and prioritizes findings by inspection risk — so you remediate what matters before an investigator sees it.

Yes. Data integrity is a core focus area. AcceleraQA monitors FDA, EMA, MHRA, and ICH data integrity guidance in real time, tracks enforcement actions where data integrity was cited, and provides AI-guided assessment tools aligned with ALCOA+ principles, 21 CFR Part 11, and Annex 11 requirements. Our publication Data Integrity By Design provides the foundational framework our platform operationalizes.

Yes. AcceleraQA is designed for the full clinical research ecosystem — sponsors, CROs, sites, and quality oversight functions. The platform supports third-party risk monitoring, vendor qualification intelligence, and oversight documentation that meets regulatory expectations for sponsor oversight of CRO-managed data systems and quality programs.

AcceleraQA monitors FDA (CDER, CBER, CDRH, ORA), EMA, ICH, MHRA, Health Canada, TGA, PMDA, and other major global regulatory bodies. Coverage includes guidance documents, enforcement actions, inspection findings, warning letters, consent decrees, and regulatory announcements — continuously updated and interpreted by our AI for operational relevance.

Request access using the form on this page. Our team will reach out to understand your organization's regulatory profile and compliance priorities, then configure platform access for your use case. We offer both individual and enterprise deployments with role-based access and organization-wide visibility features.

Yes. AcceleraQA is built for regulated industries and maintains GDPR-ready data handling practices. Enterprise-grade security, encryption, and access controls protect your organization's data. All system design and data governance practices are aligned with the regulatory expectations we monitor and publish on.

Yes. The AcceleraQA Regulatory Intelligence Newsletter is available on Substack with free and paid tiers. Free subscribers receive weekly regulatory updates and enforcement headlines. Paid subscribers get in-depth enforcement analysis, inspection preparation strategies, and practitioner commentary. Subscribe at acceleraqa.substack.com.

Reach us at info@acceleraqa.com or use the contact form on this page. We welcome inquiries about platform access, enterprise licensing, speaking engagements, bulk book orders, and partnership opportunities.